David S. Pfarr

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

Syd Johnson, Cynthia N. Oliver, Gregory A. Prince et al. · The Journal of Infectious Diseases · 1997 · 641 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17

Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

Herren Wu, David S. Pfarr, Syd Johnson et al. · Journal of Molecular Biology · 2007 · 382 citations

Veterinary Medicine, Immunology, Infectious Diseases +16

Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization

Herren Wu, David S. Pfarr, Ying Tang et al. · Journal of Molecular Biology · 2005 · 208 citations

Life Sciences, Immunology, Infectious Diseases +16

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

Ronald Herbst, Yue Wang, Sandra Gallagher et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 137 citations

Life Sciences, Hematology, Immunology +15

Isolation and Characterization of Monoclonal Antibodies Which Neutralize Human Metapneumovirus In Vitro and In Vivo

Nancy D. Ulbrandt, Hong Ji, Nita Patel et al. · Journal of Virology · 2006 · 113 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17